The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...

Only a few patients have undergone an intensive gene therapy cure for sickle cell disease since it was approved by the FDA ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...

Astellas' aspirations in gene therapy have been knocked back by a series of setbacks, including cases of liver toxicity and deaths in a trial of its AT132 gene therapy candidate for rare disease X ...

The sequencing of normal DNA and tumour DNA is now common practice. However, there is little use for large-scale genome or exome sequencing of patient and tumour DNA in the clinical environment ...

GT-0002X is under clinical development by Gene Therapy Research Institution and currently in Phase II for Parkinson's Disease.

Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached its primary endpoint in a Phase III study in paediatric patients aged two to 17 with type II ...

Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

Novartis NVS announced positive top-line results from the late-stage STEER study on experimental candidate intrathecal ...

Novartis has reported positive topline outcomes from the Phase III STEER trial of an investigational gene therapy, ...